GLP-1-induced gastroparesis

What is GLP-1-induced gastroparesis?

Gastric emptying delayed enough to cause persistent nausea, vomiting or food sitting undigested.

A 2023 JAMA cohort study (Sodhi et al., PMID 37796527) found a 3.7-fold increase in clinically diagnosed gastroparesis against bupropion-naltrexone. Risk climbs with higher doses, faster titration and pre-existing diabetic autonomic neuropathy; symptoms usually settle within four to eight weeks of reducing or stopping.

Related reading: GLP-1 Side Effect Timeline tool

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where GLP-1-induced gastroparesis comes up on this site

Other terms under Side effects

• Cholelithiasis
• Ileus
• Telogen effluvium
• Ozempic face
• Medullary thyroid carcinoma (MTC)
• Lean mass loss
• Pancreatitis (acute)
• Pancreatic cancer risk (GLP-1 myth check)
• Lipohypertrophy

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers